VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | KRd vs KTd followed by K maintenance or control for high-risk myeloma

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on research investigating whether carfilzomib in combination with either lenalidomide and dexamethasone or thalidomide and dexamethasone overcomes the negative impact of high-risk cytogenetics in newly-diagnosed multiple myeloma (MM). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter